Hepatitis C virus (HCV)
infection affects over 170 million people worldwide and is the most common
blood-borne infection in the United States. Standard treatment with peginterferon alfa-
ribavirin results in low sustained virologic response (SVR) rates in many patients, especially those who are African-American, are coinfected with human immunodeficiency virus (HIV), or have
liver cirrhosis. Because of suboptimal SVR rates, new direct-acting
antiviral agents that target HCV viral replication steps are in development.
Boceprevir is one of the novel
NS3/4A protease inhibitors that was recently approved by the U.S. Food and Drug Administration. We evaluated the literature regarding
boceprevir by performing a MEDLINE search (January 1996-July 2011) to identify relevant clinical trials. Abstracts and poster and oral presentations from hepatology and HIV conferences were also reviewed. Potent anti-HCV activity was seen in clinical trials with
boceprevir when it was studied in HCV genotype 1-infected patients who were naïve to or had experience with HCV
therapy. Data with
boceprevir in HIV-HCV-coinfected patients are currently lacking; however, initial data on
drug-drug interactions between
boceprevir and antiretrovirals have become available. Resistance to
boceprevir has been evaluated in trials as well, although more data are needed in this area. The most common adverse events with
boceprevir included
anemia and
dysgeusia. Based on available data,
boceprevir is one of the promising novel direct-acting
antiviral agents that will likely reshape the treatment of patients with HCV
infection.